The Tara Miller Melanoma Foundation has funded…
-
...Dr. Robert Vonderheide, now Director of the Abramson Cancer Center, and team’s groundbreaking RadVax trial combining radiation to immunotherapy treatments to enhance a patient’s response.
-
...Dermatologist Dr. Todd Ridky’s research into how estrogen affects melanoma and identified a promising new target for therapy.
-
...Dr. Arjun Raj from Penn Engineering who developed single cell sequencing technology to identify why patients develop resistance to targeted therapies.
-
...Research by Dr. Ravi Amaravadi, now the Associate Director for Translational Research for the Abramson Cancer Center, which led not only to the identification of a new target for melanoma therapy but also the development of a new drug to attack that target.
-
...Research changing the way that oncologists treat melanoma by studying patients’, including Tara’s, blood and tumor samples that demonstrated patient’s immune systems response after just one dose of PD1 therapy.
-
...A first of its kind clinical trial for CAR T-cell therapy in melanoma targeting the protein cMET, led by Dr. Tara Mitchell.